Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial
Author
Flohr, CarstenRosala-Hallas, Anna
Jones, Ashley P
Beattie, Paula
Baron, Susannah
Browne, Fiona
Brown, Sara J
Gach, Joanna E
Greenblatt, Danielle
Hearn, Ross
Hilger, Eva
Esdaile, Ben
Cork, Michael J
Howard, Emma
Lovgren, Marie-Louise
August, Suzannah
Ashoor, Farhiya
Williamson, Paula R
McPherson, Tess
O'Kane, Donal
Ravenscroft, Jane
Shaw, Lindsay
Sinha, Manish D
Spowart, Catherine
Taams, Leonie S
Thomas, Bjorn R
Wan, Mandy
Sach, Tracey H
Irvine, Alan D
Gach, Joanna
Publication date
2023-09-19Subject
Dermatology
Metadata
Show full item recordAbstract
Background: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust RCT evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower resource settings.Citation
Br J Dermatol . 2023 Sep 19;ljad281Type
ArticlePMID
37722926Journal
British Journal of DermatologyPublisher
Oxford University Pressae974a485f413a2113503eed53cd6c53
10.1093/bjd/ljad281